Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
IMMUNOe Research Centers
With
Octapharma
IVIG at an immunomodulatory dose of 1 g/Kg body weight has been known to induce suppression of systemic inflammation and has been used in the treatment of autoimmune diseases. It has been proven beneficial in inflammatory conditions affecting the nervous system.
Age
4–16
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Male and female children, 4-16 years of age
Diagnosis of moderate to severe PANS based on accepted criteria
Must be willing to follow study procedures and comply with wash-out period
If using prophylactic antibiotics, must be on stable dose for 3 months
You may not be if
History of rheumatic fever, including Sydenham chorea (the neurologic manifestation)
Previous IVIG therapy within the last 6 months
Allergic reactions to blood products
Patients who, in the investigator's opinion, might not be suitable for the trial.